Preliminary Agenda

Solid Tumors: Cellular & Molecular Medicine

Mutation-Selection Balance and Compensatory Mechanisms in Tumor Evolution
Glucocorticoids and Angiogenesis
Targeting glycosaminoglycans in solid tumors
Role of calcineurin in affecting tumor growth and the formation of the tumor microenvironment

Solid Tumors: Genetic Testing & Biomarkers

The Evolution of Precision Medicine- Entering the Era of Multi-omics
Novel biomarker discovery approaches to towards precision medicine in solid tumor indications
Innovative applications of liquid biopsy: the role of soluble immuno-checkpoints
Modeling Therapy-Induced Tumor Cell State Plasticity to Identify Vulnerabilities for Reducing Disease Burden
Unleashing the potential of liquid biopsy in solid tumors: diagnosis, recurrence and resistance
Identification of Novel Biomarkers of Response to Irinotecan in Patients with Colorectal Cancer

Solid Tumors: Immuno-Oncology & Novel therapeutics

Cracking open the undruggable RAS: A Clinical Perspective
Imaging of tumor acidosis for monitoring response to novel anticancer therapies
Ion channel drugs as electroceuticals for reprogramming cancer: exploiting bioelectric controls of cell and tissue function
MET as a druggable target in solid tumors
Proteomic and N-glycome profiling of secretome from BRAFV600E mutant colon cancer cells with acquired resistance to vemurafenib

Small & Non-Small Cell Lung Cancer

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs
Tumor Endothelial Cells in NSCLC: headmasters of tumor immunity
Identification of distinct immune signatures in malignant pleural mesothelioma
Overcoming Tumor Antigen Heterogeneity in the Context of CAR T Cell therapy for Solid Tumors

Genitourinary Cancer

Age of combination therapy in the treatment of advanced RCC: can we do it better?
Potential prostate cancer targeting strategies revealed by integrative proteogenomics
The Third Dimension in Prostate Cancer
Molecular Testing and Liquid Biopsy for Ovarian Cancer
The Role of p63 in the Female Germline Fidelity and Related Cancers
Advanced ovarian cancer: exploiting exosomes to potentiate the anti-cancer immune response
Tensor-Decomposition-Based Unsupervised Feature Extraction Applied to Prostate Cancer Multiomics Data

Skin Cancer

Investigating protein- and gene-expression of 27 cytokines/chemokines in melanoma patients. Identification of a 4-genes signature
Vitiligo and vitiligo-associated markers as indicators of response to immunological checkpoint inhibitors in cutaneous melanoma
Mesenchymal stem/stromal cells and the tumor tissue microenvironment

Advanced Breast Cancer

Apocrine breast carcinoma from biomarkers to therapy
Prognostic factors on her2-positive metastatic breast cancer patients treated with trastuzumab emtansine – real-world study

Head & Neck tumors

PI3K inhibitors curtail MYC-dependent mutant p53 gain-of-function in head and neck squamous cell carcinoma
A phase I study of Affinity-tuned ICAM-1 specific CAR T against advanced thyroid cancer patients

Central Nervous System (CNS) Cancers

Combination of integrated genomics with ex vivo micro cancer drug screens to individualize brain cancer therapy
Solid Tumors: Immuno-Oncology
The Role of LIN28B Oncogene in Regulating Migration & Invasion of Neuroblastoma Cells

Preventive Oncology

The common soil hypothesis for Cancer and Cardiovascular disease: evidence from experimental and epidemiological studies
The role of General Practitioners in Cancer Control. An underexploited resource in translational oncology

Prostate cancer (mCRPC) Therapies: Satellite Symposium

Identifying emerging novel metastatic castration-resistant prostate cancer therapies; understanding PARPi in combination with AR-targeted treatments

Metastatic Urothelial Carcinoma Therapies: Satellite Symposium

Role of maintenance immunotherapy in metastatic urothelial carcinoma; which patients are eligible?

★ Agenda is being updated regularly